Currently we sit at 632M/800M shares. The company
Post# of 148154
(Total Views: 1022)
Posted On: 09/25/2021 12:01:54 PM
Currently we sit at 632M/800M shares.
The company is asking for 200M.
During 2020 to now:
We started LH (the only company in the world to do a blind trial and see results to my knowledge), we are advancing it to Phase 2/3.
We finished cd10 and cd12 and started Severe trial and got approved (likely also started now too), Critical in Brazil.
We finished mTNBC, and are finishing NASH and will be starting the next phases.
We failed with Mahboob but hired Recknor and most recent Seenu, CMC specialist that helped REGN get approval.
We are solidifying Recknors position as a BOD, Nithya Ray and Lishomwa C. Ndhlovu, M.D., Ph.D. (The HIV “CURE” guy). Aka HIV specialist
We are reducing pay of current management.
We are bringing in hero Dr. Seethmaraju and Tanya Urbach.
Dr. Seethmaraju - is a professor and internationally recognized for Lung disease and transplantation. (lung knowledge is very important (imo) to CytoDyns future considering many indications may come from this knowledge). Including But not limited to Pneumonia.
(Since she’s less known I’m posting her whole profile)
Tanya Urbach - Ms. Urbach in one of our new Nominees and was recommended by our Chairman of the Board and Chief Medical Officer. She is currently Partner/Head of Family Officers for Eagle Bay Advisors, which provides family office and investment advisory services, and also provides corporate governance and corporate finance advice to Dynepic, Inc., which provides an integrated platform to power immersive training programs for companies and U.S. military forces. From November 2020 through March 31, 2021, Ms. Urbach was a sole practitioner advising broker-dealers, investment advisers and their professionals. From January 2019 through October 2020, she was a shareholder at the law firm Markun, Zusman, Freniere & Compton in Portland, Oregon. She served as General Counsel for Paulson Investment Company, LLC, a registered broker-dealer that provides investment banking services to the Company from time to time, from July 2015 until January 2019, providing advice regarding corporate governance, securities regulatory compliance, corporate finance, and other legal and securities-related issues. Ms. Urbach earned her bachelor’s degree at University of Oregon and her law degree at Lewis & Clark Law School. She served on the Executive Committee of the Oregon State Bar Securities Regulation Section from 2007 through 2015 and 2019 to the present. She brings extensive training and expertise in the conduct of securities offerings, securities litigation, corporate finance and business growth, corporate governance, and other corporate business and legal issues to the Board.
When I read this proxy I read, Science, Trial Experience, Compliance, Funding.
Though there’s much talk about “dilution” ….the same year Tesla asked for 196M shares is the same year they rose $770 (20,066%).
I’ll dive more into it later, but as of now, anyone I got involved with this stock or talk to almost daily are “FOR” all of these.
The company is asking for 200M.
During 2020 to now:
We started LH (the only company in the world to do a blind trial and see results to my knowledge), we are advancing it to Phase 2/3.
We finished cd10 and cd12 and started Severe trial and got approved (likely also started now too), Critical in Brazil.
We finished mTNBC, and are finishing NASH and will be starting the next phases.
We failed with Mahboob but hired Recknor and most recent Seenu, CMC specialist that helped REGN get approval.
We are solidifying Recknors position as a BOD, Nithya Ray and Lishomwa C. Ndhlovu, M.D., Ph.D. (The HIV “CURE” guy). Aka HIV specialist
We are reducing pay of current management.
We are bringing in hero Dr. Seethmaraju and Tanya Urbach.
Dr. Seethmaraju - is a professor and internationally recognized for Lung disease and transplantation. (lung knowledge is very important (imo) to CytoDyns future considering many indications may come from this knowledge). Including But not limited to Pneumonia.
(Since she’s less known I’m posting her whole profile)
Tanya Urbach - Ms. Urbach in one of our new Nominees and was recommended by our Chairman of the Board and Chief Medical Officer. She is currently Partner/Head of Family Officers for Eagle Bay Advisors, which provides family office and investment advisory services, and also provides corporate governance and corporate finance advice to Dynepic, Inc., which provides an integrated platform to power immersive training programs for companies and U.S. military forces. From November 2020 through March 31, 2021, Ms. Urbach was a sole practitioner advising broker-dealers, investment advisers and their professionals. From January 2019 through October 2020, she was a shareholder at the law firm Markun, Zusman, Freniere & Compton in Portland, Oregon. She served as General Counsel for Paulson Investment Company, LLC, a registered broker-dealer that provides investment banking services to the Company from time to time, from July 2015 until January 2019, providing advice regarding corporate governance, securities regulatory compliance, corporate finance, and other legal and securities-related issues. Ms. Urbach earned her bachelor’s degree at University of Oregon and her law degree at Lewis & Clark Law School. She served on the Executive Committee of the Oregon State Bar Securities Regulation Section from 2007 through 2015 and 2019 to the present. She brings extensive training and expertise in the conduct of securities offerings, securities litigation, corporate finance and business growth, corporate governance, and other corporate business and legal issues to the Board.
When I read this proxy I read, Science, Trial Experience, Compliance, Funding.
Though there’s much talk about “dilution” ….the same year Tesla asked for 196M shares is the same year they rose $770 (20,066%).
I’ll dive more into it later, but as of now, anyone I got involved with this stock or talk to almost daily are “FOR” all of these.
(21)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼